Comparative Pharmacology
Head-to-head clinical analysis: LO LARIN FE versus PIRMELLA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO LARIN FE versus PIRMELLA 1 35.
LO LARIN FE vs PIRMELLA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) inhibits gonadotropin release, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
One tablet orally once daily for 28 consecutive days. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. Active tablets (21 days) followed by ferrous fumarate 75 mg inert tablets (7 days).
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
None Documented
None Documented
Ethinyl estradiol: ~13-17 hours; norethindrone: ~8-12 hours; steady-state achieved within 5-7 days; clinical significance: missed doses may require backup contraception.
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
Renal: 30-50% as ethinyl estradiol metabolites and norethindrone metabolites; fecal: 30-50% primarily as norethindrone metabolites; biliary excretion contributes to enterohepatic circulation.
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive